Dr. O'Neil Discusses Napabucasin With FOLFIRI and Bevacizumab in CRC

Bert H. O'Neil, MD
Published: Wednesday, Jul 05, 2017



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses napabucasin with FOLFIRI and bevacizumab (Avastin) in colorectal cancer (CRC).

Data presented on the FOLFIRI arm showed that napabucasin could be given orally at 240 mg twice daily along with a full dose of FOLFIRI, says O’Neil. The cohort was then expanded to 82 patients.

Early findings indicate a response rate of about 20% for this combination for both unexposed patients and patients who have had therapy with irinotecan.
 


Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses napabucasin with FOLFIRI and bevacizumab (Avastin) in colorectal cancer (CRC).

Data presented on the FOLFIRI arm showed that napabucasin could be given orally at 240 mg twice daily along with a full dose of FOLFIRI, says O’Neil. The cohort was then expanded to 82 patients.

Early findings indicate a response rate of about 20% for this combination for both unexposed patients and patients who have had therapy with irinotecan.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x